Medscape8d
Anti–IL-23 Therapy Might Emerge as Best Biologic in Psoriasis if Used Early and at High Doses
In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...
Healio4d
Addressing skin disease with medications alone is ‘not enough,’ diet also brings benefits
Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
Interleukin-targeting biologics associated with lower infection rates in older psoriatic patients
Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...
Healio3d
IL-23 inhibitors may reduce psoriatic arthritis risk among patients with psoriasis
Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
The American Journal of Managed Care9d
Biologics Linked to Lower Infection Risk in Older Adults With Psoriatic Disease
IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.
Sacramento Bee4d
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Infliximab, a TNF-α inhibitor, is a widely used biologic ... psoriatic arthritis, and plaque psoriasis. Globally, infliximab (including biosimilars) generated approximately $6.3 billion in ...